摘要
目的探讨不同剂量米非司酮应用在围绝经期子宫肌瘤诱导绝经中的临床效果,并分析米非司酮的有效剂量。方法方便选择该院2015年8月—2016年9月期间所收治的138例围绝经期子宫肌瘤诱导绝经患者作为该次研究对象,按照应用米非司酮剂量的不同进行分组,A组,B组和C组每组46例,A组患者剂量为12.5 mg/d,B组剂量为10 mg/d,C组剂量为5 mg/d,治疗3个月后,观察3组患者的子宫体积与肌瘤体积,并记录6个月后的诱导绝经情况。结果 3组患者治疗后的子宫体积与肿瘤体积明显低于治疗前,且A组治疗后的子宫体积(104.1±14.8)mm3与肌瘤体积(24.8±3.4)mm3明显优于B组和C组,组间差异有统计学意义(t=9.561 2,2.984 9;3.070 4,3.093 1,P<0.05),A组患者中成功诱导绝经率为89.13%,明显高于B组(58.69%)和C组(63.04%),A组患者月经复潮率为6.52%,显著低于B组(21.74%)和C组(19.56%),A组患者阴道出血发生率为4.35%,显著低于B组(19.56%)和C组(17.39%),3组差异有统计学意义(P<0.05)。结论不同剂量米非司酮应用在围绝经期子宫肌瘤诱导绝经中的效果显著,但是每天应用12.5 mg剂量的米非司酮能够有效提升诱导绝经成功率,属于最佳剂量,值得临床应用。
Objective To study the clinical effect different doses of mifepristone in the hysteromyoma induced menopause during the peri-menopausal period and analyze the effective dose of mifepristone. Methods 138 cases of patients with hysteromyoma induced menopause admitted and treated in our hospital from August 2015 to September 2016 were convenient selected and divided into three groups with 46 cases in each, the doses in the group A, in the group B and in the group C were respectively 12.5 mg/d, 10 mg/d and 5 mg/d, and the uterine volume and hysteromyom volume of the three groups after3-month treatment were observed, and the induced menopause after 6-month was recorded. Results The uterine volume and hysteromyom volume of the three groups were obviously lower than those before treatment, the uterine volume and hysteromyom volume in the group A were（104.1±14.8）mm^3 and（24.8±3.4）mm^3, which were obviously better than those in the group B and in the group C, and the differences between groups were obvious（t=9.561 2,2.984 9,3.070 4,3.093 1,P〈0.05）,and the successful rate of induced menopause rate in the group A was obviously higher than that in the group B and in the group C,（89.13% vs 58.69%, 63.04%）, and the menstrual recurrence rate in the group A was obviously lower than that in the group B and in the group C,（6.52% vs 21.74%, 19.56%）, and the incidence rate of vaginal bleeding in the group A was obviously lower than that in the group B and in the group C,（4.35% vs 19.56%, 17.39%）, and the difference between the three groups was obvious, with statistical significance. Conclusion The effect of different doses of mifepristone in the hysteromyoma induced menopause during the peri-menopausal period is obvious, but the application of 12.5 mg mifepristone per day can effectively improve the successful rate of hysteromyoma induced menopause, which is the best dose, and it is worth clinical application.
作者
赵利利
ZHAO Li-li(Department of Gynecology and Obstetrics,Zaozhuang Mining Group Tengnan Hospital,Zaozhuang,Shandong Province,277519 China)
出处
《中外医疗》
2018年第10期117-118,121,共3页
China & Foreign Medical Treatment
关键词
米非司酮
围绝经期
子宫肌瘤
诱导绝经
Mifepristone
Peri-menopausal period
Hysteromyoma
Induced menopause
